Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediPharm LabsFRA:MLZ 3-Year EBITDA Growth Rate is 45.30% as of Jun. 2026, which is 6% below its 10-year median of 48.20. The stock has 4 warning signs investors should review. Among 810 Drug Manufacturers companies, MediPharm Labs ranks better than 87.41% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 45.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 49.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of MediPharm Labs was 57.80% per year. The lowest was 22.50% per year. And the median was 48.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
MediPharm Labs 3-Year EBITDA Growth Rate Related Terms
FRA:MLZ vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediPharm Labs 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where MediPharm Labs's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 45.30% mean?
MediPharm Labs (FRA:MLZ) has a 3-Year EBITDA Growth Rate of 45.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for MediPharm Labs and its competitors. This is near median its historical median of 48.20. Over the past decade, MediPharm Labs' 3-Year EBITDA Growth Rate has ranged from 22.50 to 57.80. According to the industry distribution chart, MediPharm Labs ranks #102 out of 810 companies in the Drug Manufacturers industry, placing it in the top 12.6%.
Is MediPharm Labs' 3-Year EBITDA Growth Rate too high?
MediPharm Labs' current 3-Year EBITDA Growth Rate of 45.30% is near median its 10-year median of 48.20. Over the past 10 years, this metric has ranged from a low of 22.50 to a high of 57.80. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. MediPharm Labs' value of 45.30% is 409% above this industry median. Based on the distribution chart, MediPharm Labs ranks #102 out of 810 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does MediPharm Labs' 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MediPharm Labs ranks #102 out of 810 companies for 3-Year EBITDA Growth Rate. This places MediPharm Labs in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. MediPharm Labs' value of 45.30% is 409% above this benchmark. Historically, MediPharm Labs' own 3-Year EBITDA Growth Rate has ranged from 22.50 to 57.80 over the past decade. While the company's 10-year median is 48.20 vs. the industry median of 8.90, MediPharm Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediPharm Labs's current 3-Year EBITDA Growth Rate of 45.30% is 409% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for MediPharm Labs and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediPharm Labs's current 3-Year EBITDA Growth Rate is 45.30%, which is near median its own 10-year median of 48.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (FRA:MLZ) is currently considered Fairly Valued. The stock's GF Value™ is €0.04, compared to a current price of €0.04 — trading 3.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 45.30%, which is near median its 10-year median of 48.20 and 409% above the Drug Manufacturers industry median of 8.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For MediPharm Labs (FRA:MLZ), the current 3-Year EBITDA Growth Rate is 45.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MLZ has been successfully added to your 
